GlaxoSmithKline Obtains Additional Approval For Anti-Influenza Drug RELENZA In Japan
Tue, 21 Feb 2006 10:00 AM EST
... GlaxoSmithKline (GSK) has obtained approval for additional indication for RELENZA (zanamivir), its proprietary agent for treating influenza A and B virus infections, from the Ministry of Health, Labor and Welfare. RELENZA is now available in the treatment of influenza for children aged 5 or older... click link for more info. ...

Not Signed In -


